|
VAL-CARP
Valsartan Cardio-Renal Protection
Ongoing trial
 |
Author(s) |
Ikeda N, Nishimura S, Kyo S, Komiyama N, Matsumoto K, Inoue T, Suzuki H
|
 |
Title(s) |
Valsartan Cardio-Renal Protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial. Rationale and design
|
|
Reference(s) |
Circ J 2006;70:548–52
|
|
Disease |
Renal failure |
|
Purpose |
To determine the incidence of contrast-induced nephropathy after coronary angiography, efficacy and safety of valsartan alone or in combination with an ACE inhibitor and the incidence of renal artery stenosis in patients undergoing non-emergent cardiac catheterisation with chronic renal failure |
|
Study design |
Randomised, open, parallel-group
|
|
Follow-up |
Aim 3 years
|
|
Patients |
Aim 500 patients, aged 40–80 years, with glomerular filtration rate 30–89 ml/min, undergoing non-emergent cardiac catheterisation
|
|
Treatment regimen |
Valsartan, 10 mg/day, titrated to 40 mg/day, plus an ACE inhibitor at the discretion of the physician
|
|
Results |
Not yet available
|
|
|
|
